In a landmark move for the global cardiovascular medical device sector, Pulnovo Medical has successfully finalized an oversubscribed $100 million strategic financing round. This capital infusion was led by Medtronic, one of the world’s largest medical technology companies, signaling a robust vote of confidence in Pulnovo’s proprietary Pulmonary Artery Denervation (PADN) technology. The funding round also saw significant participation from a consortium of elite global investors, including existing backers EQT, Gaorong Ventures, Lilly Asia Ventures, OrbiMed, and Qiming Venture Partners. Additionally, the round welcomed new institutional support from HSG (formerly Sequoia China), further diversifying the company’s capital base as it transitions into its next phase of international growth.
The primary objective of this strategic investment is to bolster Pulnovo Medical’s clinical development programs and expedite its global regulatory roadmap. The funds are earmarked for several critical areas: advancing international clinical trials, securing regulatory submissions in key markets, and building out a comprehensive international commercialization infrastructure. Furthermore, the company plans to invest heavily in its underlying technology platform to explore broader applications of its denervation expertise in treating cardiopulmonary diseases.
To steer this ambitious global agenda, Pulnovo has strengthened its executive leadership team with the appointment of Andre Xiao as Chief Strategy Officer. Xiao joins the firm with a distinguished background in global finance, having previously held senior roles at prominent investment firms Citadel and Millennium Management. In his new capacity, Xiao will be responsible for overseeing Pulnovo’s global financing strategies and orchestrating the company’s expansion into major international markets, ensuring that the firm’s financial and strategic initiatives align with its long-term vision of becoming a global leader in the medtech space.
A Strategic Synergy with Medtronic
Central to this announcement is a comprehensive commercial agreement between Pulnovo Medical and Medtronic. This partnership is designed to explore and exploit potential commercialization opportunities by leveraging Medtronic’s vast, world-class global commercial infrastructure. By tapping into Medtronic’s established sales networks, regulatory expertise, and deep-rooted relationships with healthcare providers worldwide, Pulnovo aims to significantly accelerate the market penetration of its PADN system.
The agreement focuses on achieving commercial synergy, combining Pulnovo’s innovative product portfolio with Medtronic’s operational scale. For Medtronic, the investment represents a strategic alignment with a disruptive technology that addresses a significant unmet need in the treatment of pulmonary hypertension and related cardiopulmonary conditions. For Pulnovo, the partnership provides a "fast-track" to global markets that would otherwise take years to penetrate independently. This collaboration is expected to strengthen Pulnovo’s market presence and provide clinicians worldwide with a new tool to manage complex cardiopulmonary mechanisms.
Understanding the PADN Technology and its Clinical Impact
Pulnovo Medical’s flagship innovation, the Pulmonary Artery Denervation (PADN) system, is a first-in-class medical device designed to treat pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension. The PADN procedure involves the use of radiofrequency ablation to target and neutralize overactive sympathetic nerves located near the bifurcation of the pulmonary artery. By reducing sympathetic nerve activity, the PADN system helps to lower pulmonary vascular resistance and decrease pulmonary artery pressure, thereby alleviating the workload on the right side of the heart.
Cardiopulmonary conditions, particularly PAH, are notoriously difficult to treat and often carry a poor prognosis. Conventional pharmacological treatments frequently fail to halt the progression of the disease, leading to right heart failure and death. Pulnovo’s PADN system offers a minimally invasive interventional alternative that addresses the underlying neuro-hormonal mechanisms of the disease.
To date, the company has successfully completed approximately 1,500 PADN procedures globally. This extensive real-world experience is backed by regulatory approvals in seven countries, where the technology is already making a difference in patient outcomes. Clinical data from these procedures have consistently demonstrated improvements in six-minute walk distances, hemodynamic parameters, and overall quality of life for patients who have exhausted traditional medical therapies.
Regulatory Milestones and the Path to the US Market
A critical component of Pulnovo’s growth strategy is its expansion into the United States, the world’s largest medical device market. The company has already made significant strides in this regard, having received the U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its PADN system. This designation is reserved for medical devices that provide for more effective treatment of life-threatening or irreversibly debilitating diseases and allows for an expedited review process.
In addition to the breakthrough status, Pulnovo has initiated two fully approved Investigational Device Exemption (IDE) trials in the U.S. These trials are being led by world-renowned clinical experts, including Dr. Gregg Stone, a senior faculty member and professor at Mount Sinai. Dr. Stone’s involvement underscores the clinical importance of the PADN technology and provides the high-level academic oversight necessary to secure eventual FDA Premarket Approval (PMA). These trials are designed to provide the rigorous, randomized controlled data required by U.S. regulators and payers to validate the safety and efficacy of the PADN procedure on a global scale.
The Global Burden of Pulmonary Hypertension
The urgency behind Pulnovo’s mission is driven by the staggering global prevalence of pulmonary hypertension (PH). It is estimated that millions of people worldwide suffer from various forms of PH, a condition characterized by high blood pressure in the arteries of the lungs. If left untreated, the average survival rate for patients with severe PAH is significantly lower than many forms of cancer.
The economic burden of the disease is equally significant, involving frequent hospitalizations, expensive long-term medication regimens, and a substantial loss of productivity. By offering a procedural solution that can potentially reduce the reliance on lifelong high-cost medications and prevent the progression to heart failure, Pulnovo’s PADN system presents a compelling value proposition for healthcare systems looking to manage the costs of chronic disease.
Evolution of a Global Platform
The recent $100 million round follows a successful Series C financing closed in March 2025, where the company also secured $100 million. The continuity of funding at this scale highlights the rapid pace of Pulnovo’s development and the sustained interest from the investment community. Cynthia Chen, Chairlady and President of Pulnovo Medical, emphasized that this latest round marks a "pivotal transition" for the organization.
"Through the integration of industry expertise and long-term capital, Pulnovo is building a scalable growth model anchored in proprietary innovation, global clinical development, and strategic ecosystem partnerships," Chen stated. "This financing marks a pivotal transition from a product-driven phase to a fully integrated global platform. As we continue to strengthen our capabilities across both clinical and technological fronts, we remain committed to delivering meaningful innovation to patients worldwide."
This shift from a "product-driven" to a "platform-driven" company suggests that Pulnovo intends to expand its technological applications beyond the initial scope of PADN. The company’s expertise in intravascular denervation could potentially be applied to other autonomic nervous system disorders, positioning Pulnovo as a broader player in the interventional cardiovascular space.
Market Analysis and Future Implications
The partnership between Medtronic and Pulnovo is indicative of a broader trend in the medtech industry, where established giants are increasingly looking toward agile, innovation-focused startups to fill gaps in their portfolios. For Medtronic, investing in Pulnovo provides a hedge and a strategic entry point into the pulmonary hypertension market, complementing its existing strengths in renal denervation and heart failure management.
For the wider medical community, the success of Pulnovo’s PADN system could herald a new era in the treatment of pulmonary vascular diseases. If the ongoing U.S. IDE trials yield positive results, it could lead to a shift in clinical guidelines, positioning pulmonary artery denervation as a standard of care alongside or even ahead of certain pharmacological interventions.
The involvement of a diverse group of investors—ranging from healthcare-specialist funds like OrbiMed and Lilly Asia Ventures to generalist powerhouses like the former Sequoia China—ensures that Pulnovo has the financial resilience to navigate the complex and costly landscape of global clinical trials. As the company moves toward commercialization in the U.S. and Europe, the focus will likely shift toward market access, reimbursement strategies, and physician education.
Chronology of Key Milestones
The journey of Pulnovo Medical is marked by a series of rapid-fire successes that have brought it to its current standing:
- Initial R&D Phase: Development of the proprietary radiofrequency ablation catheter and generator specifically tuned for pulmonary artery tissue.
- First-in-Human Trials: Successful completion of early-stage trials demonstrating the safety and feasibility of the PADN procedure.
- Regulatory Expansion: Securing approvals in seven countries and performing over 1,500 procedures, establishing a robust safety profile.
- FDA Breakthrough Status: Recognition by the U.S. FDA, providing a streamlined path for the PADN system’s entry into the American market.
- Series C Financing (March 2025): Raising $100 million to initiate global clinical trials and expand business operations.
- Strategic Financing Round (2026): Securing $100 million led by Medtronic, accompanied by a strategic commercial agreement and the appointment of Andre Xiao as CSO.
As Pulnovo Medical looks toward the future, the integration of Medtronic’s commercial prowess with Pulnovo’s technological innovation sets a high bar for the cardiovascular device industry. The company is now uniquely positioned to address the global challenge of cardiopulmonary disease, with the capital, leadership, and partnerships necessary to turn its vision into a global clinical reality. The coming years will be defined by the results of its U.S. trials and the subsequent rollout of the PADN system across international healthcare systems, potentially transforming the lives of millions of patients suffering from pulmonary hypertension.